All
Survival Benefits with Keytruda and Padcev in Advanced Urothelial Cancer
January 28th 2024Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.
No Increased Blood-Related Side Effects With Radium-223 in Prostate Cancer
January 27th 2024Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.
Nubeqa, Hormone Therapy May Reduce Hospitalizations in Prostate Cancer
January 27th 2024Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.
Max Hypofractionated Concurrent Chemoradiation Dose Identified in NSCLC
January 25th 2024Researchers claim to have determined the maximum=tolerated dose and usage of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy boost for patients with locally advanced unresectable non-small cell lung cancer, according to recently published findings.
Laughter Therapy May Improve Mood, Decrease Pain in Patients With Cancer
January 24th 2024This study assessed the impact of laughter therapy in both patients with cancer and caregivers, and both groups showed decreases in mood disturbances, in addition to decreases in pain for patients and in burnout for caregivers.
Fruzaqla Delays Colorectal Cancer Progression, Prolongs Patient Survival
January 23rd 2024Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.